119 related articles for article (PubMed ID: 36625758)
1. Self-Adjuvanting Protein Vaccine Conjugated with a Novel Synthetic TLR4 Agonist on Virus-Like Liposome Induces Potent Immunity against SARS-CoV-2.
Ding D; Wen Y; Liao CM; Yin XG; Zhang RY; Wang J; Zhou SH; Zhang ZM; Zou YK; Gao XF; Wei HW; Yang GF; Guo J
J Med Chem; 2023 Jan; 66(2):1467-1483. PubMed ID: 36625758
[TBL] [Abstract][Full Text] [Related]
2. Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern.
Wang J; Wen Y; Zhou SH; Zhang HW; Peng XQ; Zhang RY; Yin XG; Qiu H; Gong R; Yang GF; Guo J
J Med Chem; 2022 Feb; 65(3):2558-2570. PubMed ID: 35073081
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern.
Zhang RY; Zhou SH; He CB; Wang J; Wen Y; Feng RR; Yin XG; Yang GF; Guo J
ACS Infect Dis; 2022 Jul; 8(7):1367-1375. PubMed ID: 35748575
[TBL] [Abstract][Full Text] [Related]
4. Novel sialoglycan linkage for constructing adjuvant-protein conjugate as potent vaccine for COVID-19.
Wen Y; Zhang RY; Wang J; Zhou SH; Peng XQ; Ding D; Zhang ZM; Wei HW; Guo J
J Control Release; 2023 Mar; 355():238-247. PubMed ID: 36716860
[TBL] [Abstract][Full Text] [Related]
5. Strategic development of a self-adjuvanting SARS-CoV-2 RBD vaccine: From adjuvant screening to enhanced immunogenicity with a modified TLR7 agonist.
Meng X; Xu Y; Yang J; Meng S; Ding N; Sun T; Zong C
Int Immunopharmacol; 2024 May; 132():111909. PubMed ID: 38554446
[TBL] [Abstract][Full Text] [Related]
6. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
7. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
8. Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses.
Qiao Y; Zhan Y; Zhang Y; Deng J; Chen A; Liu B; Zhang Y; Pan T; Zhang W; Zhang H; He X
Front Immunol; 2022; 13():992062. PubMed ID: 36569949
[TBL] [Abstract][Full Text] [Related]
9. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
10. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
[TBL] [Abstract][Full Text] [Related]
11. A Novel Targeted RIG-I Receptor 5'Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine.
Bai Y; An C; Zhang X; Li K; Cheng F; Cui B; Song Z; Liu D; Zhang J; He Q; Liu J; Mao Q; Liang Z
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243185
[TBL] [Abstract][Full Text] [Related]
12. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
[TBL] [Abstract][Full Text] [Related]
13. The synthesis and preliminary immunological evaluation of a dual-adjuvant SARS-CoV-2 RBD vaccine: Covalent integration of TLR7/8 and iNKT cell agonists.
Xu Y; Yang J; Meng X; Meng S; Sun T; Ding N; Zong C
Int J Biol Macromol; 2024 Jun; 270(Pt 1):132258. PubMed ID: 38735613
[TBL] [Abstract][Full Text] [Related]
14. Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Horvath D; Temperton N; Mayora-Neto M; Da Costa K; Cantoni D; Horlacher R; Günther A; Brosig A; Morath J; Jakobs B; Groettrup M; Hoschuetzky H; Rohayem J; Ter Meulen J
Sci Rep; 2023 Mar; 13(1):4648. PubMed ID: 36944687
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.
Atalis A; Keenum MC; Pandey B; Beach A; Pradhan P; Vantucci C; O'Farrell L; Noel R; Jain R; Hosten J; Smith C; Kramer L; Jimenez A; Ochoa MA; Frey D; Roy K
J Control Release; 2022 Jul; 347():476-488. PubMed ID: 35577151
[TBL] [Abstract][Full Text] [Related]
16. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
[TBL] [Abstract][Full Text] [Related]
17. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
18. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2.
Moshref Javadi M; Taghdisi Hosseinzadeh M; Soleimani N; Rommasi F
Microb Pathog; 2022 Sep; 170():105687. PubMed ID: 35917987
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.
Routhu NK; Cheedarla N; Bollimpelli VS; Gangadhara S; Edara VV; Lai L; Sahoo A; Shiferaw A; Styles TM; Floyd K; Fischinger S; Atyeo C; Shin SA; Gumber S; Kirejczyk S; Dinnon KH; Shi PY; Menachery VD; Tomai M; Fox CB; Alter G; Vanderford TH; Gralinski L; Suthar MS; Amara RR
Nat Commun; 2021 Jun; 12(1):3587. PubMed ID: 34117252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
